Inquiry into Hyponatraemia-related Deaths

The Hyponatraemia-related Deaths Inquiry, chaired by Mr Justice O'Hara, examined the deaths of children in Northern Ireland hospitals and the subsequent handling of these cases by the healthcare system. The inquiry, which reported in January 2018 after being established in 2004, made 96 recommendations aimed at improving paediatric care, clinical governance, and the handling of serious adverse incidents.

The Department of Health accepted 91 recommendations (95%) and accepted in principle a further 5 recommendations (5%). According to implementation status data from January 2024, 65 recommendations (68%) are recorded as completed, while 31 (32%) remain stalled.

The evidence indicates progress in several areas of paediatric care. Trusts have published policies on age-appropriate care settings, implemented consultant-led ward rounds in children's wards, and established senior lead nurse roles. Documentation standards have been updated to require recording of clinical discussions and handovers, with serum sodium recording on fluid balance charts implemented. Family involvement protocols have been established with guidance on meaningful engagement throughout investigation processes.

In terms of clinical governance, the Being Open Framework has been implemented across Trusts with staff training on duty of candour principles. Chief Executive accountability for SAI investigations has been established in governance frameworks, and multi-disciplinary review processes have been incorporated into investigation procedures.

However, significant recommendations remain outstanding. The statutory duty of candour legislation, while subject to public consultation in 2020-2021, has not yet been enacted. The recommendation for a fully independent external investigation unit has been accepted but not established, with the response noting that independent investigation arrangements have been 'strengthened' instead. Several other recommendations, including those relating to workforce planning and the Patient Advocacy Service, show limited evidence of progress beyond initial acceptance.

The implementation programme updates from January 2024 indicate that work continues on many recommendations six years after the report's publication, though specific details of progress on individual recommendations are limited in the available evidence.